State Street Corp Acquires 7,763 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

State Street Corp raised its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 717,387 shares of the medical instruments supplier’s stock after purchasing an additional 7,763 shares during the period. State Street Corp owned approximately 1.64% of Harvard Bioscience worth $1,930,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in HBIO. GSA Capital Partners LLP bought a new stake in shares of Harvard Bioscience in the third quarter valued at approximately $30,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Harvard Bioscience during the 2nd quarter worth $31,000. SG Americas Securities LLC bought a new position in shares of Harvard Bioscience in the third quarter worth $36,000. Avior Wealth Management LLC raised its stake in Harvard Bioscience by 1,118.1% in the third quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 13,373 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Harvard Bioscience during the second quarter worth about $40,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Trading Up 4.5 %

Shares of Harvard Bioscience stock opened at $2.11 on Thursday. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience, Inc. has a 12-month low of $1.95 and a 12-month high of $5.43. The company has a market capitalization of $92.03 million, a price-to-earnings ratio of -6.39 and a beta of 1.27. The firm’s 50-day moving average price is $2.24 and its two-hundred day moving average price is $2.63.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.